Internal Medicine, Endocrinology, Diabetes, & Metabolism · Tucson, AZ
NPI
1194974519
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2380 N Ferguson Ave Ste 104
Tucson, AZ, 85712
Phone (520) 324-1010
Groups this clinician bills Medicare through
Medicare paid, 2024
$57K
1,219 services
Medicare patients, 2024
345
Average age 74
Drug cost, 2024
$1.9M
4,432 prescriptions
Company payments, 2025
$755
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shubh P Kaur was code 99214 (office e&m - established), 491 times for 278 patients. In total Shubh P Kaur billed 1,219 services in 14 codes, and Medicare paid $57K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 491 | 278 | $71.42 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 313 | 213 | $12.89 | $4,033 |
| 95251 Test - Miscellaneous | Facility | 156 | 82 | $26.98 | $4,209 |
| 99204 Office E&M - New | Facility | 52 | 52 | $94.85 | $4,932 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $104.43 | $1,253 |
By year: 2022 $56K for 1,625 services; 2023 $57K for 1,001 services; 2024 $57K for 1,219 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 42 | 41 | $7.41 | $311 |
| 83036 Blood Count | 33 | 31 | $7.85 | $259 |
Medicare prescription drug claims, 2024
In 2024, the drug Shubh P Kaur prescribed most often to Medicare patients was Levothyroxine Sodium, with 621 prescriptions and refills. In total Shubh P Kaur wrote 4,432 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 621 | 1,733 | 178 | $7,857 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 237 | 535 | 71 | $35K |
| Metformin Hcl Generic | 235 | 647 | 74 | $1,612 |
| Trulicity Dulaglutide | 149 | 237 | 43 | $235K |
| Ozempic Semaglutide | 144 | 263 | 46 | $243K |
| Atorvastatin Calcium Generic | 139 | 380 | 41 | $1,284 |
| Farxiga Dapagliflozin Propanediol | 124 | 264 | 37 | $141K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 121 | 250 | 39 | $12K |
| Methimazole Generic | 118 | 336 | 35 | $1,397 |
| Liothyronine Sodium Generic | 112 | 337 | 35 | $3,796 |
| Lisinopril Generic | 111 | 335 | 38 | $747 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 90 | 200 | 35 | $9,628 |
| Humalog Kwikpen U-100 Insulin Lispro | 89 | 197 | 30 | $24K |
| Jardiance Empagliflozin | 88 | 217 | 29 | $129K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 83 | 145 | 25 | $51K |
Brand drugs: 2,096 claims; generic drugs: 1,780 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shubh P Kaur $755 ($755 in general payments such as food, travel and fees) from 14 companies. The largest payer was Sequel Med Tech, LLC with $178.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 2 | $178 |
| Insulet Corporation PODD | 3 | $90.87 |
| Xeris Pharmaceuticals, Inc. | 4 | $86.46 |
| Novo Nordisk Inc NVO | 5 | $81.77 |
| KVK-Tech, Inc. | 1 | $56.3 |
| Amgen Inc. AMGN | 3 | $47.45 |
| Medtronic, Inc. MDT | 2 | $41.14 |
| Corcept Therapeutics CORT | 2 | $35.91 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $32.36 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $28.44 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.